Regulation - Xolair

Filter

Current filters:

Xolair

Popular Filters

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

24-01-2014

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given…

Cardio-vascularEuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryXolair

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Back to top